| Trial Name | Clinicaltrials.gov NCT Number |
|---|---|
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | NCT04449549* |
| 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People with Advanced Solid Tumors | NCT03366116 |
| Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors | NCT04222413 |
| Measuring the Effects of Talazoparib in Patients with Advanced Cancer and DNA Repair Variations | NCT04550494** |
| Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | NCT03816345 |
| Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors, DURVA+ Trial | NCT03907475 |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | NCT04750928 |
| Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients with Tumors That Have Alterations in DNA Repair Genes | NCT05687110 |
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors | NCT05687136 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination with an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | NCT05711615 |
| Studying TAK-243 in Patients with Advanced Cancer | NCT06223542 |
| Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients with Metastatic Solid Cancers | NCT06606990 |
| Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | NCT05691491 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | NCT05564377 |
| Study of Chemotherapy Plus Ipatasertib for People with Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial | NCT05554380 |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | NCT05638295 |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | NCT05554328 |
| A Phase 2 Study of Atezolizumab with Selinexor in Alveolar Soft Part Sarcoma (AXIOM) | NCT05333458 |
| Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly Selected Solid Tumors (ComBET) | NCT05327010 |
| Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors | NCT05691517 |
*Study is open only for the following histologic subtypes: clear cell ovarian cancer, anal cancer, granulosa cell ovarian cancer, and ewing sarcoma
** Prior PARP required